Back to Search Start Over

Analysis of trio test in neurodevelopmental disorders.

Authors :
Kim SH
Kwon SS
Lee JS
Kim HD
Lee ST
Choi JR
Shin S
Kang HC
Source :
Frontiers in pediatrics [Front Pediatr] 2022 Dec 23; Vol. 10, pp. 1073083. Date of Electronic Publication: 2022 Dec 23 (Print Publication: 2022).
Publication Year :
2022

Abstract

Background: Trio test has been widely used for diagnosis of various hereditary disorders. We aimed to investigate the contribution of trio test in genetically diagnosing neurodevelopmental disorders (NDD).<br />Methods: We retrospectively reviewed 2,059 NDD cases with genetic test results. The trio test was conducted in 563 cases. Clinical usefulness, optimal timing, and methods for the trio test were reviewed.<br />Results: Pathogenic or likely pathogenic variants were detected in 112 of 563 (19.9%) patients who underwent the trio test. With trio test results, the overall diagnostic yield increased by 5.4% (112/2,059). Of 165 de novo variants detected, 149 were pathogenic and we detected 85 novel pathogenic variants. Pathogenic, de novo variants were frequently detected in CDKL5 , ATP1A3 , and STXBP1 .<br />Conclusion: The trio test is an efficient method for genetically diagnosing NDD. We identified specific situations where a certain trio test is more appropriate, thereby providing a guide for clinicians when confronted with variants of unknown significance of specific genes.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (© 2022 Kim, Kwon, Lee, Kim, Lee, Choi, Shin and Kang.)

Details

Language :
English
ISSN :
2296-2360
Volume :
10
Database :
MEDLINE
Journal :
Frontiers in pediatrics
Publication Type :
Academic Journal
Accession number :
36619507
Full Text :
https://doi.org/10.3389/fped.2022.1073083